Angela C. Onorato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Angela C. Onorato has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Bimal Pankaj Chaudhari
The Steve and Cindy Rasmussen Institute for Genomic Medicine, The Abigail Wexner Research Institute, Nationwide Children's Hospital Columbus Ohio USA
2 shared publications - Rachel Gosselin
Center for Cardiovascular Research, The Abigail Wexner Research Institute (R.G.), The Ohio State University College of Medicine, Columbus, OH
2 shared publications - Vidu Garg
Department of Pediatrics The Ohio State University College of Medicine Columbus Ohio USA
2 shared publications - Amee M. Bigelow
The Heart Center, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH, 43205, USA.
1 shared publication - Chance Alvarado
The Ohio State University Wexner Medical Center
1 shared publication - Isaac Kistler
Statistics and Biostatistics Analyst II, Center for Biostatistics, Department of Biomedical Informatics, Nationwide Children’s Hospital, Columbus, USA
1 shared publication
Latest Publications
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (2) , e005527
Assessing Genetic Testing in Adult Congenital Heart Disease: Current State and Patient Perspectives
BACKGROUND: Genetic variation affects clinical outcomes, prognosis, and family planning decisions in individuals with congenital heart disease (CHD). While genetic testing recommendations for infants and children with CHD have expanded, similar broad guidelines are lacking for patients with adult CHD (ACHD). Here, we investigated the current state of genetic testing in patients with ACHD and their perceptions toward testing, which has not been previously reported. METHODS: A single-center prospective cohort survey of patients with ACHD aged ≥18 years was evaluated in a large ACHD clinic over a 12-month period. RESULTS: Among 336 survey respondents (median age, 29 years; 52% male), CHD lesions were wide ranging, albeit largely represented by conotruncal (35%) or left ventricular outflow tract (35%) lesions. Most patients did not have children (64%) or a family history of CHD (79%). Thirteen percent had evidence of prior genetic testing despite 41% to 98% meeting criteria by current pediatric recommendations. Most desired genetic testing (68%) though interest varied by sex, education level, and family status. Individual and family health factors were reported as the most influential considerations for genetic testing. CONCLUSIONS: Few patients with ACHD have had genetic testing despite most being eligible based on current pediatric guidelines, likely related to birth era. Patients were interested in genetic testing though demographic factors and family status affected interest. The lack of broad recommendations for genetic testing in the ACHD population likely represents a significant barrier to increased utilization of genetic tests.
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (2) , e005527
Assessing Genetic Testing in Adult Congenital Heart Disease: Current State and Patient Perspectives
BACKGROUND: Genetic variation affects clinical outcomes, prognosis, and family planning decisions in individuals with congenital heart disease (CHD). While genetic testing recommendations for infants and children with CHD have expanded, similar broad guidelines are lacking for patients with adult CHD (ACHD). Here, we investigated the current state of genetic testing in patients with ACHD and their perceptions toward testing, which has not been previously reported. METHODS: A single-center prospective cohort survey of patients with ACHD aged ≥18 years was evaluated in a large ACHD clinic over a 12-month period. RESULTS: Among 336 survey respondents (median age, 29 years; 52% male), CHD lesions were wide ranging, albeit largely represented by conotruncal (35%) or left ventricular outflow tract (35%) lesions. Most patients did not have children (64%) or a family history of CHD (79%). Thirteen percent had evidence of prior genetic testing despite 41% to 98% meeting criteria by current pediatric recommendations. Most desired genetic testing (68%) though interest varied by sex, education level, and family status. Individual and family health factors were reported as the most influential considerations for genetic testing. CONCLUSIONS: Few patients with ACHD have had genetic testing despite most being eligible based on current pediatric guidelines, likely related to birth era. Patients were interested in genetic testing though demographic factors and family status affected interest. The lack of broad recommendations for genetic testing in the ACHD population likely represents a significant barrier to increased utilization of genetic tests.
- Open Access
- 1 February 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (2) , 44
Diagnostic yield of exome and genome sequencing for critically ill pediatric cardiac patients
Genetic testing guidelines for children in cardiac intensive care units (CICUs) remain limited despite a high prevalence of genetic diseases among this population. Advances in next-generation sequencing technologies, especially exome sequencing (ES) and genome sequencing (GS), enable more comprehensive genetic evaluations than traditional testing modalities such as chromosomal microarray (CMA). While testing recommendations exist for cardiomyopathies and arrhythmias, broad application of next-generation sequencing, especially ES/GS, across indications for admission to CICU has not been recommended amongst cardiology societies. We aimed to evaluate the diagnostic efficacy of ES/GS in critically ill pediatric patients with cardiac disease. Retrospective chart review of patients who underwent clinical ES/GS in a quaternary hospital’s pediatric CICU between January 2020 and August 2023. Patient demographics and clinical characteristics were collected and analyzed. Results were compared by test type, cardiac phenotype, and extracardiac anomalies status. Forty-five patients underwent clinical ES/GS, with median age at testing of 33 [7–905] days. Primary cardiac phenotypes included congenital heart disease (CHD), ventricular dysfunction, and arrhythmia. Diagnostic results were found in 20 patients (44.4%) with 18/20 (90%) linked to cardiac phenotypes. Diagnostic yield was not different among cardiac phenotype groups but was higher in patients with extracardiac anomalies. Notably, gene panels would have failed to make 36% of diagnoses made by ES/GS. ES and GS provided high diagnostic yield in critically ill cardiac patients across various phenotypes. As next-generation sequencing technologies and interpretation capabilities mature, diagnostic abilities in pediatric cardiac disease will continue to advance.
- 1 February 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (2) , 44
Open AccessDiagnostic yield of exome and genome sequencing for critically ill pediatric cardiac patients
Genetic testing guidelines for children in cardiac intensive care units (CICUs) remain limited despite a high prevalence of genetic diseases among this population. Advances in next-generation sequencing technologies, especially exome sequencing (ES) and genome sequencing (GS), enable more comprehensive genetic evaluations than traditional testing modalities such as chromosomal microarray (CMA). While testing recommendations exist for cardiomyopathies and arrhythmias, broad application of next-generation sequencing, especially ES/GS, across indications for admission to CICU has not been recommended amongst cardiology societies. We aimed to evaluate the diagnostic efficacy of ES/GS in critically ill pediatric patients with cardiac disease. Retrospective chart review of patients who underwent clinical ES/GS in a quaternary hospital’s pediatric CICU between January 2020 and August 2023. Patient demographics and clinical characteristics were collected and analyzed. Results were compared by test type, cardiac phenotype, and extracardiac anomalies status. Forty-five patients underwent clinical ES/GS, with median age at testing of 33 [7–905] days. Primary cardiac phenotypes included congenital heart disease (CHD), ventricular dysfunction, and arrhythmia. Diagnostic results were found in 20 patients (44.4%) with 18/20 (90%) linked to cardiac phenotypes. Diagnostic yield was not different among cardiac phenotype groups but was higher in patients with extracardiac anomalies. Notably, gene panels would have failed to make 36% of diagnoses made by ES/GS. ES and GS provided high diagnostic yield in critically ill cardiac patients across various phenotypes. As next-generation sequencing technologies and interpretation capabilities mature, diagnostic abilities in pediatric cardiac disease will continue to advance.